The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.
Company profile
Ticker
LMNX
Exchange
Website
CEO
Nachum Shamir
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Luminex International, Inc. • Luminex B.V. • Luminex 2 B.V. • Luminex 3 B.V. • Luminex Debt Holding, LLC • Nanosphere, LLC • Luminex Molecular Diagnostics, Inc. • Luminex Trading (Shanghai) Company Limited, a limited liability company • Luminex Japan Corporation Ltd. • Labpac Pty Ltd ...
IRS number
742747608
LMNX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
26 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
Transcripts
LMNX
Earnings call transcript
2020 Q4
9 Feb 21
LMNX
Earnings call transcript
2020 Q3
8 Nov 20
LMNX
Earnings call transcript
2020 Q2
4 Aug 20
LMNX
Earnings call transcript
2020 Q1
4 May 20
LMNX
Earnings call transcript
2019 Q4
10 Feb 20
LMNX
Earnings call transcript
2019 Q3
4 Nov 19
LMNX
Earnings call transcript
2019 Q2
31 Jul 19
LMNX
Earnings call transcript
2019 Q1
6 May 19
LMNX
Earnings call transcript
2018 Q4
4 Feb 19
LMNX
Earnings call transcript
2018 Q3
5 Nov 18
Financial summary
Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 271.56 mm | 271.56 mm | 271.56 mm | 271.56 mm | 271.56 mm | 271.56 mm |
Cash burn (monthly) | 12.62 mm | (no burn) | (no burn) | (no burn) | 7.19 mm | (no burn) |
Cash used (since last report) | 453.45 mm | n/a | n/a | n/a | 258.34 mm | n/a |
Cash remaining | -181.89 mm | n/a | n/a | n/a | 13.22 mm | n/a |
Runway (months of cash) | -14.4 | n/a | n/a | n/a | 1.8 | n/a |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|